Randomized Trial of Myeloablative Conditioning Regimens: Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine - Lee, Je-Hwan; Joo, Young-Don; Kim, Hawk; Ryoo, Hun Mo; Kim, Min Kyoung; Lee, Gyeong-Won; Lee, Jung-Hee; Lee, Won-Sik; Park, Jae-Hoo; Bae, Sung-Hwa; Hyun, Myung Soo; Kim, Dae-Young; et al. (Journal of clinical oncology, 2013)
Keywords: Adolescent; Adult; Aged; Biological and medical sciences; Busulfan - adverse effects; Busulfan - therapeutic use; Cyclophosphamide - adverse effects; Cyclophosphamide - therapeutic use; Drug Therapy, Combination; Female; Gastroenteritis - etiology; Graft vs Host Disease - etiology; Hematopoietic Stem Cell Transplantation - adverse effects; Hematopoietic Stem Cell Transplantation - methods; Humans; Leukemia - therapy; Male; Medical sciences; Middle Aged; Multivariate Analysis; Myeloablative Agonists - adverse effects; Myeloablative Agonists - therapeutic use; Myelodysplastic Syndromes - therapy; Survival Analysis; Transplantation Conditioning - methods; Transplantation, Homologous; Treatment Outcome; Tumors; Vidarabine - adverse effects; Vidarabine - analogs & derivatives; Vidarabine - therapeutic use; Young Adult; Antineoplastic agent; Purine nucleotide; Alkanediol; Nucleotide analog; Alkanesulfonic acid; Alkylating agent; Oxazaphosphinane derivatives; Cyclophosphamide; Randomization; Cancerology; Fludarabine; Antimetabolic; Nitrogen mustard; Clinical trial; Myelosuppression; Fluorine Organic compounds; Busulfan; Conditioning; Comparative study